Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis
Sponsor: Genentech, Inc.
This PHASE4 trial investigates Granulomatosis With Polyangiitis and Microscopic Polyangiitis and is currently completed. Genentech, Inc. leads this study, which shows 9 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE4
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE4
-
May 2018 — Jun 2018 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Feb 2017 — May 2018 [monthly]
Active Not Recruiting PHASE4
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE4
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Boston, United States